Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China,
Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China,
Am J Nephrol. 2021;52(6):507-518. doi: 10.1159/000516187. Epub 2021 Jun 16.
A working group on the Oxford classification of IgA nephropathy (IgAN) recently reported that crescents detected in the kidney tissue predicted a worse renal outcome. However, the effect of C1 lesion (crescents in <1/4th of all glomeruli) and their volume on the prognosis of IgAN is still unclear. We explored the association of C1 lesion with the renal prognosis in IgAN patients without obvious chronic renal lesions (glomerulosclerosis <25%, T score <2).
We investigated 305 biopsy-proven IgAN patients without obvious chronic renal lesions. Clinicopathologic features and treatment modalities were recorded. The patients were divided into several groups according to the presence or absence of a global crescent: no crescent (NC) group, only segmental crescent (SC) group, and global crescent (GC) group. The outcome was the survival from a combined event defined by a ≥15% decline in the estimated glomerular filtration rate (eGFR) after 1 year or ≥30% decline in the eGFR after 2 years.
Among all patients, 75.7% were in the NC group, 14.8% were in the SC group, and 9.5% were in the GC group. Compared with the NC group, patients in the SC group and the GC group had more urine protein, lower eGFR, and presented with more severe pathological change. During a median follow-up of 34.8 (26.16-57.95) months, the combined event occurred in 34 individuals (11.1%). In a multivariate model, the GC group (HR = 2.756, 95% CI = 1.068-7.109) was associated with an increased risk of the combined event.
In IgAN patients without obvious chronic renal lesions, the GC group had more severe clinical and pathological manifestations than in the NC group. GC is an independent risk factor for the progression of IgAN renal function.
最近,一个关于 IgA 肾病(IgAN)牛津分类的工作组报告称,肾脏组织中检测到的新月体预示着更差的肾脏预后。然而,C1 病变(新月体占所有肾小球的<1/4)及其体积对 IgAN 预后的影响尚不清楚。我们探讨了 C1 病变与无明显慢性肾脏病变(肾小球硬化<25%,T 评分<2)的 IgAN 患者的肾脏预后的关系。
我们调查了 305 例经活检证实的无明显慢性肾脏病变的 IgAN 患者。记录了临床病理特征和治疗方式。根据是否存在弥漫性新月体,将患者分为无新月体(NC)组、节段性新月体(SC)组和弥漫性新月体(GC)组。终点是由 1 年后估算肾小球滤过率(eGFR)下降≥15%或 2 年后 eGFR 下降≥30%定义的联合事件的生存情况。
所有患者中,75.7%为 NC 组,14.8%为 SC 组,9.5%为 GC 组。与 NC 组相比,SC 组和 GC 组患者的尿蛋白更多,eGFR 更低,且病理变化更严重。在中位随访 34.8(26.16-57.95)个月期间,有 34 例患者(11.1%)发生了联合事件。在多变量模型中,GC 组(HR=2.756,95%CI=1.068-7.109)与联合事件风险增加相关。
在无明显慢性肾脏病变的 IgAN 患者中,GC 组的临床和病理表现比 NC 组更严重。GC 是 IgAN 肾功能进展的独立危险因素。